NSCLC molecular portrait of the sample of Czech population and indications of targeted therapy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F13%3A%230000179" target="_blank" >RIV/26475821:_____/13:#0000179 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

čeština

Original language name

NSCLC molecular portrait of the sample of Czech population and indications of targeted therapy

Original language description

Czech Republic belongs to countries with high lung cancer incidence. In 2010 there were diagnosed in 4636 men (incidence 89.8/100 000) and in 1887 women (incidence 35.2). In the same year there were 3998 lung cancer deaths in men´s population (mortality77.5/100 000) and 1556 women´s population (mortality 29.0/100 000). 85% of the patients were diagnosed as advanced stages of disease (stage III and IV). Molecular therapy targeted on tumour driving mutations should improve quality of life, PFS and overalsurvival in NSCLC patients. While EGFR mutations are widely used as indicator of gefitinib and erlotinib for the first line treatment of advanced NSCLC, recently, translocation of EML-4 ALK and ROS 1 amplification, should serve as a guide for indicationof crizotinib. Some other genetic changes, like EGFR amplification, c-met amplification, PIK3CA1 mutations and K-ras mutations should serve as prognostic or predictive factors of targeted therapy actually or in near future.

Czech name

NSCLC molecular portrait of the sample of Czech population and indications of targeted therapy

Czech description

Czech Republic belongs to countries with high lung cancer incidence. In 2010 there were diagnosed in 4636 men (incidence 89.8/100 000) and in 1887 women (incidence 35.2). In the same year there were 3998 lung cancer deaths in men´s population (mortality77.5/100 000) and 1556 women´s population (mortality 29.0/100 000). 85% of the patients were diagnosed as advanced stages of disease (stage III and IV). Molecular therapy targeted on tumour driving mutations should improve quality of life, PFS and overalsurvival in NSCLC patients. While EGFR mutations are widely used as indicator of gefitinib and erlotinib for the first line treatment of advanced NSCLC, recently, translocation of EML-4 ALK and ROS 1 amplification, should serve as a guide for indicationof crizotinib. Some other genetic changes, like EGFR amplification, c-met amplification, PIK3CA1 mutations and K-ras mutations should serve as prognostic or predictive factors of targeted therapy actually or in near future.

Type

O - Miscellaneous

CEP classification

EB - Genetics and molecular biology

OECD FORD branch

—

Project

<a href="/en/project/NR9087" target="_blank" >NR9087: Use of molecular predictors for optimum selection of targeted therapy of non-small cell lung cancer</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2013

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů